| |
original article |
Date |
Title |
Authors All Authors |
| 1 |
[GO] |
2023―Feb―16 |
Effect of DPP4/CD26 expression on SARS-CoV-2 susceptibility, immune response, adenosine (derivatives m62A and CD) regulations on patients with cancer and healthy individuals |
Jiaman Du, Jiewen Fu, Wenqian Zhang, Lianmei Zhang, Hanchun Chen, Jingliang Cheng, et al. (+2) Tao He, Junjiang Fu |
| 2 |
[GO] |
2022―Feb―28 |
Correlation of SARS-CoV-2 to cancer: Carcinogenic or anticancer? (Review) |
Ying-Shuang Li, Hua-Cheng Ren, Jian-Hua Cao |
| 3 |
[GO] |
2020―Dec―14 |
Immune-checkpoint inhibitors from cancer to COVID-19: A promising avenue for the treatment of patients with COVID-19 (Review) |
Silvia Vivarelli, Luca Falzone, Francesco Torino, Giuseppa Scandurra, Giulia Russo, Roberto Bordonaro, et al. (+4) Francesco Pappalardo, Demetrios Spandidos, Giuseppina Raciti, Massimo Libra |
| 4 |
[GO] |
2020―May―26 |
Pan-cancer analysis of transmembrane protease serine 2 and cathepsin L that mediate cellular SARS-CoV-2 infection leading to COVID-19 |
Periklis Katopodis, Vladimir Anikin, Harpal Randeva, Demetrios Spandidos, Kamaljit Chatha, Ioannis Kyrou, Emmanouil Karteris |
|
